Last $15.78 USD
Change Today 0.00 / 0.00%
Volume 0.0
KIN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

kindred biosciences inc (KIN) Snapshot

Open
$15.43
Previous Close
$15.78
Day High
$16.46
Day Low
$15.41
52 Week High
03/14/14 - $26.99
52 Week Low
12/12/13 - $8.75
Market Cap
310.5M
Average Volume 10 Days
65.7K
EPS TTM
--
Shares Outstanding
19.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KINDRED BIOSCIENCES INC (KIN)

Related News

No related news articles were found.

kindred biosciences inc (KIN) Related Businessweek News

View More BusinessWeek News

kindred biosciences inc (KIN) Details

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its primary small molecule product candidates include CereKin, an oral interleukin-1 beta inhibitor for osteoarthritis pain and inflammation in dogs; AtoKin, a beef-flavored formulation of fexofenadine for atopic dermatitis in dogs; and SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs, cats, and horses. The company's other small molecule product candidates consist of KIND-007, an inhibitor of Bruton’s tyrosine kinase, an enzyme important in certain lymphomas and immune-mediated human diseases; and KIND-006, a promotility agent for gastrointestinal diseases in cats. It also has a pipeline of biologic product candidates, including KIND-502, a new biologic that targets the canine counterpart of the human target for Xolair, for allergic and immune-mediated diseases; KIND-506, a new biologic that targets the canine counterpart of the human target for Enbrel, for inflammatory and autoimmune diseases; KIND-507, a new biologic that targets the canine counterpart of the human target for Orencia, for immune-mediated diseases; KIND-504, a cancer vaccine, in which the active ingredient has demonstrated efficacy in certain types of cancers in humans and in dogs, various checkpoint inhibitors, and feline erythropoietin; and KIND-501, an antiangiogenic biologic for cancer in dogs. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.

12 Employees
Last Reported Date: 03/31/14
Founded in 2012

kindred biosciences inc (KIN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $486.3K
Co-Founder, Chief Operating Officer and Secre...
Total Annual Compensation: $214.1K
Chief Scientific Officer and Head of Research...
Total Annual Compensation: $95.3K
Compensation as of Fiscal Year 2013.

kindred biosciences inc (KIN) Key Developments

Kindred Biosciences, Inc. - Shareholder/Analyst Call

To provide an overview of strategies and Stephen Sundlof, D.V.M, Ph.D., will offer insights into the animal health business from an FDA perspective

Kindred Biosciences, Inc. Presents at 11th Annual Craig-Hallum Institutional Investor Conference, May-28-2014

Kindred Biosciences, Inc. Presents at 11th Annual Craig-Hallum Institutional Investor Conference, May-28-2014 . Venue: Minneapolis Marriott City Center Hotel, 30 South Seventh Street, Minneapolis, MN 55402, United States.

Kindred Biosciences, Inc. Presents at 11th Annual Dental & Veterinary Conference, May-28-2014 10:55 AM

Kindred Biosciences, Inc. Presents at 11th Annual Dental & Veterinary Conference, May-28-2014 10:55 AM. Venue: The Peninsula Hotel, 700 Fifth Avenue at 55th Street, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KIN:US $15.78 USD 0.00

KIN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aratana Therapeutics Inc $12.59 USD +0.03
View Industry Companies
 

Industry Analysis

KIN

Industry Average

Valuation KIN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KINDRED BIOSCIENCES INC, please visit www.kindredbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.